IMPORTANCE Radiation therapy (RT) is a critical cancer treatment, but the existing radiation oncologist work force does not meet growing global demand. One key physician task in RT planning involves tumor segmentation for targeting, which requires substantial training and is subject to significant interobserver variation.
L ung cancer remains the second most common cancer, and leading cause of cancer mortality, in the United States 1 with approximately 150 000 deaths estimated in 2018. Radiation therapy (RT) plays a critical role in the treatment of this disease, and 20% of early stage (I-II) and 50% of advanced stage (III-IV) lung cancer patients receive RT 2 with
projections of approximately 96 000 patients requiring this treatment modality in 2020. 2, 3 The precise and accurate volumetric segmentation of tumors, which determines where the radiation dose is delivered into the patient, is a critical part of RT targeting and planning, and has a direct impact on tumor control and radiation-induced toxic effects. Typically, tumor segmentation is performed manually, slice-by-slice on computed tomography (CT) scans by trained radiation oncologists ( Figure 1 ) (eFigure 1 in the Supplement)andcanbeextremely time consuming. However, there is significant interobserver variation even among experts (eg, 7-fold variation among 5 experts in 1 study), 4,5 and the quality of segmentation may directly impact clinical outcomes. [6] [7] [8] Even in prospective clinical trials with prespecified RT parameters, major RT planning deviations occur in 8% to 71% of patients and are associated with increased mortality and treatment failure. Unlike cancer image analysis for diagnostic purposes, which produces a single binary answer (yes or no) to a single question ("Is a mass present?"), therapeutic tumor segmentation involves interpretation of medical imaging on a voxelby-voxel basis to classify cancer vs normal organ and incorporates an intrinsic risk-benefit assessment of where the radiation dose is to be delivered. For an expert radiation oncologist, this requires both training and intuition, and experience may directly impact lung cancer outcomes. 10 However, this critical human resource is not accessible to many underserved patients in both the United States and globally.
11,12
Although approximately 58% of lung cancer cases occur in less developed countries, 13 these countries have a staggering shortage of radiation oncologists, with an estimated 23 952 radiation oncologists required in 84 low-and middle-income countries by 2020 yet only 11 803 were available in 2012. 14 We used a novel combined approach of crowd innovation and artificial intelligence (AI) to address this unmet need in global cancer care. Crowd innovation has been successfully applied to a variety of genomic and computational biology problems by using prize-based competitions to identify extreme value solutions that outperform those developed by conventional academic approaches. [15] [16] [17] [18] Online contests expand the pool of potential problem solvers substantially beyond traditional academic expert circles to include individuals with a more diverse set of skills, experience, and perspectives. Artificial intelligence has been successfully applied to diagnostic subspecialties of medicine, such as pathology and radiology. Examples include diagnosis of skin cancers from photographs, 19 lung cancer on screening CT images, 20,21 retinal diseases using optical coherence tomography, 22 and breast cancer using mammograms, 23 or pathology specimens. 24 However, applying AI techniques to therapeutic processes in medicine has not been equally well explored because of a lack of large data sets that are well curated by medical experts, and the need for AI techniques capable of adjusting to alterations in practice patterns or risk tolerance and style of individual treating physicians for specific diseases.
To address the global shortage of expert radiation oncologists, we designed a crowd innovation contest to challenge an international community of programmers to rapidly produce automated AI algorithms that could replicate the manual lung tumor segmentations of an expert radiation oncologist. To reach this goal, we developed a novel contest design, including:
Key Points
Question Can crowd innovation be used to rapidly prototype artificial intelligence (AI) solutions that automatically segment lung tumors for radiation therapy targeting, and can AI performance match expert radiation oncologists for this time-and training-intensive task?
Findings A 3-phase, prize-based crowd innovation challenge over 10 weeks, including 34 contestants who submitted 45 algorithms, identified multiple AI solutions that replicated the accuracy of an expert radiation oncologist in targeting lung tumors and performed the task more rapidly.
Meaning On-demand, crowdsourcing methods can be used to rapidly prototype AI algorithms to replicate and transfer expert skill and knowledge to underresourced health care settings and improve the quality of radiation therapy globally. 1. A well-curated lung tumor data set segmented by an expert clinician for contestants to train and test their algorithms. 2. An objective scoring system for automatic evaluation of submitted algorithms to provide contestant feedback and final rankings. 3. Motivating and guiding contestants to produce clinically relevant solutions with a cost-effective prize pool, information sharing, and access to feedback from the expert clinician.
Methods

Data Set Curation
To encompass a range of tumor biology and size, we collected a data set of 461 patients with stage IA to IV non-small cell lung cancer (NSCLC) with planning CT scans obtained prior to RT under a protocol approved by the institutional review board at the Dana-Farber/Harvard Cancer Center. A waiver of informed consent was granted due to the retrospective data collection. The data set comprised 77 942 images (median, 157 images/scan) of which 8144 images had tumor present. All tumors were segmented by a single expert (R.H.M.) with 4 years of RT specialty training and 7 years of subspecialty experience in treating lung cancers. The data set was anonymized and randomly divided by patient into training (n = 229), validation (n = 96), and holdout test sets (n = 136). Additional information is available in the eMethods section of the Supplement.
Tumor Characteristics
The Additional patient and tumor summary statistics are provided in the Table.
Contest Design
We conducted our contest on Topcoder.com (Wipro, Bengalaru, India), a commercial platform that hosts online algorithm challenges for a community of more than 1 000 000 programmers who compete for prizes while solving computational problems. The contest was designed with 3 interconnected phases with the results of each phase informing the design of subsequent phases. Participants were oriented to the underlying medical problem and the contest design through online written materials and a video (https://youtu.be/An-YDBjFDV8)ofthe clinician expert demonstrating the manual lung tumor segmentation task. The first 2 phases each ran for 3 weeks over 70 calendar days and offered $35 000 and $15 000 prize pools (eTable 1 in the Supplement), respectively, with entry open to anyone registered on the Topcoder platform. The third invitation-only phase ran for 4 weeks, with an additional approximately $5000 in prizes.
Segmentation Scoring
The contestants' algorithms were scored by comparing the volumetric segmentation produced by each algorithm on a given patient's CT scan (including all CT slices) against the expert's segmentation. The performance of the contestants' algorithms were assessed using a custom segmentation score (S score) (eTable 2 in the Supplement), that incorporated both the impact of relative and absolute errors. A higher score reflects an automated segmentation for a given patient's entire tumor that has a high level of both relative and absolute overlap with the expert's segmentation. Incorporating absolute error was particularly important in this therapeutic RT segmentation task because missing any volume of tumor would lead to an RT miss and increased likelihood of tumor recurrence. We also analyzed performance using traditional measures of relative error, including the Dice coefficient (Dice) and Jaccard index. 
Contest Execution
Participants were provided with the full training set (CT scans, expert lung tumor and organ segmentations, and other clinical data), and the CT scans without segmentations from a validation set. During each phase, contestants produced segmentations using their algorithms on the validation set and received real-time evaluation of their algorithm's performance based on the S score on a public leaderboard. With this feedback, contestants could modify their solution or generate new approaches to improve their scores. At the end of each phase, participants submitted their final algorithms for independent evaluation by the study team on the holdout test data set (which was not available to the contestants), and prizes were distributed to contestants who submitted algorithms generating the highest scores.
Between each phase, the study team including the clinical expert reviewed the winning algorithms' performance and segmentations on individual patient scans to revise the contest design and objectives in each subsequent phase. In the first phase, the contestants were tasked with producing an algorithm that would both locate the tumor and replicate the expert's segmentations. After review of phase 1 performance identified deficiencies in tumor localization as the major limiting factor, the contest was redesigned in phase 2 to allow contestants to focus their efforts on the therapeutic task of lung tumor targeting, as opposed to the distinct task of tumor diagnosis. Accordingly, we identified tumor location by providing a randomly generated seed point within each tumor, and asked the contestants to optimize their algorithms with that a priori knowledge.
The top 5 contestants from phase 2 were invited to work with the investigators in a collaborative phase 3 challenge to address deficits observed in the phase 2 solutions. The collaborative model allowed contestants to work together to improve algorithm performance.
Benchmarks
We compared the performance of the top AI algorithms from each phase against benchmarks including: (1) a commercially available, semi-automated segmentation software program (MIM Maestro, MIM Software) with and without human optimization of parameters; (2) the interobserver variation in manual segmentations between R.H.M. and 5 radiation oncologists in a previously published and publicly available, 26,27 but similar external data set of 21 patients with lung cancer planned for RT (21 CT scans; median 178 images per scan; 3666 images in total; mean, roughly 226 images with tumor present); (3) intraobserver variation in the human expert performing the same segmentation task twice (independently, 3 months apart). Furthermore, we validated algorithm performance and assessed for overfitting by applying the winning algorithms to the external, independent data set above. We estimated efficiency gains by comparing speed of expert manual segmentation vs the winning algorithms.
Results
Contest Participation
A total of 564 contestants from 62 countries registered for this challenge, and 34 (6%) submitted algorithms, including 244 unique submissions in phase 1 (mean, 8.4/participant), 164 in phase 2 (mean, 14.9/participant), and 180 in phase 3 (mean, 36/participant). Forty-five of these algorithms were submitted for the final scoring (phase 1, 29; phase 2, 11; and phase 3, 5). From these, we collected 10 independent, winning algorithms (eFigure 4 in the Supplement) developed by 9 unique winners.
Contest Results
Performance results for each phase are provided in eTable 3 in the Supplement; and Figure 2 . For phase 1, the top 7 algorithms had average S scores on the holdout data set ranging from 0.15 to 0.38, and suboptimal performance using relative measures of error. The average S scores for phase 2 increased to 0.53 to 0.57, with a similar improvement in other performance metrics. In phase 3, performance of the top algorithm increased by an additional 9%. Combining the top 5 algorithms from phase 2 and phase 3 using an ensemble model (selected based on performance on the validation set; eMethods in the Supplement), yielded an additional 9% to 12% improvement in performance with a final S score reaching 0.68. The algorithms performed well for a variety of clinical situations and tumor locations (eFigures 1 and 5 in the Supplement).
Characteristics of the Winning Algorithms
The top contestants used a variety of approaches, including convolutional neural networks (CNNs), cluster growth, and random forest algorithms (eTable 4 in the Supplement). Solutions based on CNNs involved both custom and published architectures and frameworks to perform the tasks of object detection and localization (eg, Overfeat 28 ), and/or segmentation (eg, SegNet 29-31 and U-Net 32 ). The latter were originally developed for the purpose of facial detection, biomedical image segmentation and road scene segmentation for autonomous vehicles research and adapted for the present task. The phase 3 algorithms produced segmentations at rates between 15 seconds/scan to 2 minutes/scan.
Comparison With Benchmarks
Examples of segmentations generated by human expert, commercially available software and contest algorithms are shown in Figure 1 ; and eFigure 1 in the Supplement. The phase 2 algorithms performed better than a commercially available, threshold-based autosegmentation software (eTable 3 in the Supplement) ( Figure 2 ). The winning phase 3 algorithm and the ensemble models achieved scores within the interobserver variation and comparable to the interobserver mean between 5 other radiation oncologists and the expert from this study. Although the ensemble solution did not exceed the performance of the intraobserver benchmark ( Figure 2 and Figure 3 ), approximately 75% of ensemble segmentations exceeded an S score of 0.60 (the lower threshold of intraobserver performance) which suggests that the contest produced algorithms capable of matching expert performance. In addition, the performance of the contest's top algorithms and the ensemble in the independent, external data set matched or exceeded their performance in the contest data set (eTable 3 in the Supplement). The mean time for the expert to perform manual segmentations was 8 minutes (range, 1-23 minutes), substantially longer than even the slowest algorithm.
Discussion
The results of this study show that a combined approach that leverages crowd innovation to access computational expertise to develop AI algorithms coupled with human medical expert feedback can enable rapid development of multiple solutions for a complex medical task with performance comparable to human experts.
Implications for Cancer Care
The ability to rapidly develop high-performing AI algorithms for tumor segmentation via a cost-effective crowd innovation approach has the potential to substantially improve the quality of oncologic care globally. Developing AI solutions for time-intensive tasks such as tumor segmentation can increase productivity and time with patients for busy clinicians by reducing computer-based work, and solve the known oncology workforce crisis (eg, number of trained radiation oncologists) in under-resourced health care systems worldwide.
12 Artificially intelligent algorithms can also replicate and transfer expert-level knowledge for education, training, and/or quality assurance to raise the quality of global RT care. Providing quality assurance for RT trials is particularly important because variation in radiation planning even in highly structured protocols may be substantial enough to negatively impact outcomes and drive the results of trials toward the null. 9 In addition, the ability to generate automatic tumor segmentations rapidly and accurately could revolutionize therapeutic response assessment in oncology in general, by allowing quantitative assessments of tumor imaging features during and after treatment, which may provide better predictive capability than traditional, manual, linear measurements (eg, RECIST).
33,34
Implications for Application of AI to Radiation Therapy A comparison of average performance (point) and standard error (whiskers) based on metrics (A) Dice coefficient, (B) Jaccard Index, and (C) contest-specific segmentation score (S score) of top 7 algorithms from phase 1, top 5 algorithms from phase 2, top 5 algorithms from phase 3, phase 2 ensemble model, and phase 3 ensemble model on the validation (x axis) and holdout data sets (y axis). Performance benchmarks for comparison include commercially available region-growing-based algorithms before (commercial software) and after (commercial software and expert) human intervention, the average of human interobserver comparisons between 6 radiation oncologists, and intraobserver variation in the human expert performing the segmentation task twice independently on the same tumor. Benchmarks are shown as dashed lines (gray bands indicate estimated uncertainties as described in eTable 3 in the Supplement).
Research Original Investigation
Crowd Innovation for Artificial Intelligence-Based Solutions for Radiation Therapy Targeting nificantly outperform existing commercially-available, semi-automated segmentation tools, which have historically focused on atlas-based, 42 PET-based, 43 and single click region grow auto-segmentation 44 approaches.
Implications for Crowd Innovation in Oncology
Successful crowd innovation contests start with proper design and methodology. These findings demonstrated that a multiphase challenge design can provide agility, including opportunities for recalibrating objectives to more closely align with the desired clinical output. We opted for phased contests with shorter durations, smaller prizes, and regular feedback because the objective was rapid prototyping of optimal solutions. This methodology helped us to quickly adapt the contest objectives, by obtaining a better understanding of how nondomain expert crowds could perform on this medical task. The timely feedback from the human expert contributed to the iterative improvement in performance. For example, the expert's input regarding phase 1 algorithm performance was factored into the design of phase 2 to allow a seed point. The clinical expert was able to articulate that this would more closely resemble the clinical situation of RT planning where the clinician's task is accurate targeting of a known lung tumor. With this input, the phase 2 solution performance improved by approximately 50%. Second, we demonstrated that using different designs for different phases of the contest opened opportunities for further performance gains. With phase 3, we transitioned from a large, crowd innovation competition, to a smaller, invitation-only collaborative contest, involving the top-performing contestants from phase 2. The design encouraged participants to fine-tune the most promising solutions produced in phase 2, with further improvement in performance.
Although past contests have leveraged crowds to produce AI solutions to problems in diagnostic oncology including in the 2017 Kaggle Bowl (early lung cancer detection in low-dose CT screening scans) 45 and the 2016 DREAM Challenge (identifying breast cancer on digital mammograms) 46,47 which also used a phased approach, the study reported here applied a multiphase crowd innovation approach with collaborative components to address a therapeutic problem. Whereas diagnostic challenges have a relatively simple gold standard in a pathologic diagnosis, in contrast, solving this therapeutic problem required quality volumetric segmentations of the tumor produced by an expert. Several other differences in contest design included cumulative duration (70 days in 3 phases for ours vs 90 days for Kaggle and 17 weeks for DREAM) and considerably smaller prize pool ($55 000 vs $1 000 000). Although on-demand crowd workers are now widely used in a range of tasks (eg, ride sharing, labor market platforms like UpWork/Freelancer), our research demonstrates that crowds can also augment and complement traditional academic research with considerable cost, time, and performance benefits. As demand for AI talent increases across the economy, and new AI methods rapidly evolve across a range of academic and industrial settings, this study demonstrates that a relatively low-cost, crowd innovation approach can be used to democratize the development of AI solutions in oncology beyond traditional academic and industrial circles, by enabling individual oncologists to access AI expertise, on demand to improve their own clinical and research practices.
Limitations
The data sets used for this competition were relatively small compared with prior diagnostic radiology challenges (the Kaggle and DREAM challenge provided >1000 CTs and >600 000 mammograms, respectively), and the top algorithms likely underperform what would be observed with further training on a larger data set. However, the size of our data sets were comparable to those used in other recent applications of AI to RT, such as Google's DeepMind's efforts to automatically segment normal organs in the head and neck. 41 Thus, AI can be successfully applied to solve problems in oncology even with limited data resources. Furthermore, the production of the lung tumor segmentations relied on a single human expert, and the contest's AI algorithms may have acquired the natural biases of that expert and generated segmentations representative of the training, experience, and judgment of 1 individual rather than objective ground truth (eFigure 6 in the Supplement). Nevertheless, replicating and delivering the manual skillset and experience of a given expert may still provide considerable value in therapeutic oncology.
Conclusions
This multifaceted crowd innovation challenge demonstrated that despite conservative constraints on contest duration and cost, it was possible to produce a diverse set of tumor segmentation AI algorithms that could replicate the abilities of a human expert and were faster. Using crowd innovation to generate clinically-relevant AI algorithms will allow sharing of scarce human expertise to under-resourced health care settings to improve the quality of cancer care globally.
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Accepted for Publication: January 7, 2019. corresponding to other normal structures drawn at the time of radiation treatment planning (e.g. body, bronchi, esophagus, heart, lung, trachea; each were available for subsets of the scans) were produced using a combination of manual and/or automated segmentation tools.
Training, Validation and Holdout Test Data Sets
The curated data set was randomly divided into three disjoint subsets: a training set comprising 229 patients, a validation set comprising 96 patients and a holdout test set comprising 136 patients. The contestants were provided with the anonymized training set, which included 229 CT scans and associated primary tumor segmentation data, the additional segmentation data for ROIs corresponding to other normal structures, DICOM metadata (including pixel spacing, slice thickness and patient orientation, CT scanner type and settings), and supplementary clinical information indicating whether or not intravenous contrast agent was used for the scan. They had access to CT imaging and annotation data, and associated DICOM metadata in both the original anonymized DICOM data format and more familiar data formats (lossless PNGs, and field separated text files). In addition, the contestants were provided the 96 validation set CT scans and accompanying supplementary clinical information, but not the associated primary tumor segmentation, nor the additional segmentation data for normal structure
ROIs. The holdout test data set was withheld from the contestants during all phases.
In phase 2 and phase 3, contestants were provided boundary-avoiding seed points within each tumor ROI as additional training and validation data (seed points were withheld for the 136 patients in the holdout test set). The seed points were generated randomly based on the existing primary tumor segmentation data.
Evaluation Metric for Scoring Segmentations Generated by Contestants' Algorithms
The contestant's algorithms were scored by comparing the volumetric segmentation produced by each algorithm on a given patient's scan (including all CT slices/images in the scan) against the expert's segmentation on that same scan. A wide variety of metrics are available for evaluating the volumetric segmentation quality with respect to reference data produced either manually (e.g. radiologist or radiation oncologist) or automatically by a gold standard algorithm.
Commonly used metrics are provided for reference in eTable 2, along with the metric developed for this study (S-score). Metrics such as the Dice Coefficient (i.e., F1 score), and Jaccard Index (J) are insensitive to the absolute error in tumor volume segmentation (i.e., these metrics are invariant under scaling of the ground truth and predicted tumor volumes). From a clinical standpoint, however, the absolute error in segmentation is particularly relevant for radiation treatment of the patient, since leaving a portion of the tumor out of the segmentation will result in under-dosing of the tumor and potentially lead to the bad outcome of local tumor recurrence.
Given a truth ROI (T) which is the manually generated volumetric segmentation by the human expert, and a predicted ROI (P) automatically generated by the contestant's algorithm, the true positive 
Contest Design and Execution:
The contest was hosted on the Topcoder.com (Wipro, Bengalaru, India) online algorithm contest platform that has a community of ~1,000,000 programmers and data scientists competing regularly. The competitors were tasked with producing an automatic tumor delineation algorithm that parallels the lung tumor delineation accuracy of an "expert clinician", while exceeding the expert in processing speed and delineation consistency. The contest offered a prize pool of $50,000 for the first two phases of competition, which were open to the entire Topcoder community. Top ranking contestants from Phase 1 received prizes of: $10,000, $7,000, $5,000, $4,000, $3,000, $2,000, and $1,000, plus $3,000 in mid-contest bonus prizes and top-ranking participants of Phase 2 of the contest received prizes of: $7,000, $4,500, $2,000, $1,000 and $500 (see eTable 1). For these first two phases, the rankings were determined by the highest average S-score based on the segmentations generated by the independent application of the submitted algorithms on the holdout test set by the study team. A third invitational phase, which was restricted to the five top contestants from phase 2 and an additional participant invited from a separate contest, focused on refinement of the top algorithms from phase 2. In that phase, each contestant was awarded $500 for submitting proposals which outlined a strategy for further algorithmic improvement, and each were awarded $100 for submitting a solution, plus $15 for every At the beginning of the competition, participants were provided an introductory video explaining the background and concepts behind manual delineation of lung tumors (https://youtu.be/An-YDBjFDV8). During each phase, participants had access to the training (CT and segmentation data) and validation (CT data only) data sets (in phase 2 and phase 3, the data sets were expanded to include seed points randomly generated within the tumor region to indicate the location of each tumor as an additional input) and were permitted to submit predicted volumetric segmentations on the latter for online evaluation. Participants received real-time evaluation of their submissions, which were published on an online leaderboard, and could make multiple submissions during each contest phase with modifications in response to that feedback. To aid off-line evaluation of their algorithms during development, a proprietary visualization tool was created and provided to contestants to automatically score their segmentations and make visual and quantitative comparisons by scan and slice against the segmentations produced by the human (such comparisons were only possible on the provided training data). The source codes from each phase were released to participants in each subsequent phase of competition.
At the end of each phase, participants were invited to submit their code and trained model parameters for final validation and evaluation by the study team on the independent holdout data set, which the contestants did not have access to (see eTable 5 and 6 for full performance details). Note that by providing an online leaderboard during competition and ability to query the validation data set multiple times, there is a possibility for over-fitting algorithms to the validation data set. Thus, a crucial part of reliably assessing the true performance of the algorithms submitted required final evaluation of the algorithms in each phase of the contest on the holdout dataset, which was independent and not accessible to the contestants. The study team including the medical expert reviewed performance both in terms of the performance metrics and on an individual scan and slice-by-slice basis to identify and classify sources of systematic error. These analyses between phases were utilized to revise the contest design and objectives in each subsequent phase, but the conclusions from these internal reviews were not explicitly disclosed to the contestants to minimize biasing solutions generated in subsequent phases of the contest.
During the third invitational phase, the 5 winning participants from phase 2 were invited to collaborate with each other and receive direct input, feedback and suggestions from the human expert and other study investigators. All communications were channeled through an open online forum to ensure that all participants had access to the same information and insights. Through the clinical expert review of the segmentations generated by the winning algorithms in phase 2, a pattern of performance deficiencies was observed including very small tumors and tumors adjacent to soft tissue structures and the study investigators believed that these deficiencies could be © 2019 American Medical Association. All rights reserved. :projectData/search_field/xnat:projectData.ID/search_value/stwstrategymmd) from an external, previously published, publicly-available data set 1 , which included lung tumor segmentations from five separate expert radiation oncologists who were not involved in this current study. Although the external data set was publicly available, based on a review of the submitted codes and associated solution descriptions provided by the contestants, the external data set was not used by any of the winning competitors for the purpose of training or evaluating solutions during the competition.
Benchmarks: Post-Contest External Validation
One deficiency of our challenge design is that the winning contestants received multiple, albeit limited exposure to the holdout data set during the contest (i.e., they received a final score for their algorithm's performance once after phase 1 and once after phase 2). Although extremely infrequent, and limited in terms of the information gained, this raised the prospect of overfitting on the holdout data set. The same concerns may be raised in relation to the information sharing between the study investigators and the contestants that is inherent to competition redesigns between phases. For our study, the likelihood of making the same decisions regarding competition redesign on the basis of algorithm performance in the validation set alone is high (i.e., the sources of under-performance in both phases were clear from analysis of the validation set), and thus the potential leakage of information is likely negligible. However, one cannot preclude with certainty the possibility for overfitting on the hold-out data set through this process without more complex contest designs that better preserve the integrity of the holdout data set 2 .
In light of these concerns, we validated the phase 3 performance results by evaluated all solutions subsequent to the contest on an independent external, publicly-available data set comprising CT scans from 21 patients with lung cancer (the same was used to produce our interobserver benchmarks) which was segmented by the same human expert (R.H.M.) as the contest data set 1 . The average performance of the phase 3 algorithms on this external data set (eTable 6) is largely consistent (i.e., within 1-2 standard deviations) with that on holdout data set. The average performance across all algorithms appears to systematically exceed those obtained for the holdout data set, which may be indicative of small characteristic differences between the holdout and external data sets.
Using the same external data set, we investigated the performance of the contest algorithms, 
